Evaluation of 5-s-cysteinyldopa as a marker of melanoma progression: 10 years' experience

Melanoma Research

Volumn 12, Issue 3, 2002, Pages 245-253

  Wakamatsu, K ^a   Kageshita, T ^b   Furue, M ^c   Hatta, N ^d   Kiyohara, Y ^e   Nakayama, J ^f   Ono, T ^b   Saida, T ^g   Takata, M ^d   Tsuchida, T ^e   Uhara, H ^g   Yamamoto, A ^h   Yamazaki, N ^h   Naito, A ^a   Ito, S ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

^g SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

5 S cysteinyldopa; Disease progression; Melanoma; Tumour marker

Indexed keywords

BIOCHEMICAL MARKER; CYSTEINYLDOPA; TUMOR MARKER;

ADULT; AMELANOTIC MELANOMA; ARTICLE; CANCER GROWTH; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SERUM; SURGICAL APPROACH; ADOLESCENT; AGED; BLOOD; CANCER STAGING; CHILD; COMPARATIVE STUDY; EYE TUMOR; FOLLOW UP; JAPAN; LIFE TABLE; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COMPARATIVE STUDY; CYSTEINYLDOPA; DISEASE PROGRESSION; EYE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMAN; JAPAN; LIFE TABLES; MALE; MELANOMA; MIDDLE AGE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; HUMANS; MIDDLE AGED;

EID: 0035999091     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200206000-00008     Document Type: Article

References (35)

1. Prognostic clinical and pathological features
2. Serological markers for melanoma
3. Quantification of melanoma-associated molecules in plasma/serum of melanoma patients
4. Melanin-related metabolites as markers of melanoma: A review
5. Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase
6. Chemical analysis of melanins and its application to the study of the regulation of melanogenesis
7. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice
8. 5 Years' experience of 5-S-cysteinyldopa in melanoma diagosis
9. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: Ten years' experience of 50 patients
10. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects
11. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy
12. Evaluation of melanin-related metabolites as markers of melanoma progression
13. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression
14. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma
15. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
16. The histogenesis and biologic behavior of primary human malignant melanomas of the skin
17. Clinical study of DAV + INF-β therapy (combination adjuvant therapy with intravenous DTIC, ACNU and VCR, and local injection of INF-β) for malignant melanoma
18. Improved HPLC determination of 5-S-cysteinyldopa in serum
19. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression
20. Serum concentration of 5-S-cysteinyldopa in patients with melanoma
21. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma
22. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese
23. Exposure to sunlight and urinary excretion of 5-S-cysteinyldopa
24. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma
25. Significance of serum protein S100 levels in screening for melanoma metastasis: Do protein S100 levels enable early detection of melanoma recurrence?
26. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma
27. Serum levels of S100 protein and 5-S-cysteinyldopa as markers of melanoma progression
28. Prognostic factors in patients with metastatic malignant melanoma
29. Prognostic factors for survival of patients treated systemically for disseminated melanoma
30. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate dehydrogenase
31. Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins
32. MIA as a reliable tumor marker in the serum of patients with malignant melanoma
33. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma
34. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo
35. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients